@article{08d069177b0e4352a9c5d1decc3a3817,
title = "Reply",
author = "Orange, {Dana E.} and Blachere, {Nathalie E.} and Frank, {Mayu O.} and Salina Parveen and DiCarlo, {Edward F.} and Serene Mirza and Tania Pannellini and Jiang, {Caroline S.} and Figgie, {Mark P.} and Bykerk, {Vivian P.} and Gravallese, {Ellen M.} and Orbai, {Ana Maria} and Mackie, {Sarah L.} and Goodman, {Susan M.}",
note = "Funding Information: Supported by the NIH (National Center for Advancing Translational Sciences grant UL1‐TR‐001866 and National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 1UH2‐AR‐067691). Dr. DiCarlo has received consulting fees from Wright Medical Technology (less than $10,000). Dr. Frank has received consulting fees from the Memorial Sloan Kettering Cancer Center (less than $10,000) and from the New York Genome Cancer Center (more than $10,000). Dr. Bykerk has received consulting fees from Bristol‐Myers Squibb, Gilead Sciences, UCB, Amgen, and Sanofi (less than $10,000 each). Dr. Mackie has received consulting fees from Roche (less than $10,000) and research support from the NIHR, Vasculitis UK, and Sanofi. Dr. Goodman owns stock or stock options in Regenosine. No other disclosures relevant to this letter were reported.",
year = "2021",
month = jan,
doi = "10.1002/art.41463",
language = "English (US)",
volume = "73",
pages = "175--176",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "1",
}